Lantheus Holdings, Inc.

Worldwide revenue of $372.8 million in the first quarter 2025 GAAP fully diluted earnings per share of $1.02, compared to $1.87 in the first quarter of 2024; adjusted fully diluted earnings per share of $1.53, compared to $1.69 in the first quarter of 2024 Free cash flow totaled $98.8 million for the first quarter 2025 Closed acquisition of Evergreen Theragnostics early in the second quarter; expect to close on acquisition of Life Molecular Imaging in the coming weeks; and yesterday announced planned divestiture of SPECT business Recently announced positive data for two MK-6240 pivotal studies; plan to file NDA in the third quarter of 2025 Provided updated interim corporate guidance for full year 2025 revenue and adjusted fully diluted earnings per share

BEDFORD, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today reported financial results for its first quarter ended March 31, 2025.

"We are laying the foundation for the next chapter of Lantheus’ business with the acquisition of Evergreen Theragnostics and planned acquisition of Life Molecular Imaging, both of which add growth drivers that complement our business and diversify our revenues. These transactions also add exciting new pipeline programs in both late- and early-stage development and key capabilities that enable Lantheus to progress novel programs from bench to clinic," said Brian Markison, Chief Executive Officer at Lantheus. "With robust cash flow and a disciplined capital allocation strategy, we are advancing our position as the leading radiopharmaceutical-focused company. We remain dedicated to being the partner of choice for nuclear medicine departments and free-standing imaging centers, delivering sustainable growth, creating long-term value for our shareholders, and bringing innovative products to patients in need."

Summary Financial Results

(in millions, except per share data – unaudited)   Three Months Ended 
March 31, 2025  2024 % Change Worldwide revenue  $ 372.8  $ 370.0  0.8 % GAAP net income  $ 72.9  $ 131.1  (44.3) % GAAP fully diluted earnings per share  $ 1.02  $ 1.87  (45.5) % Adj. net income (non-GAAP)  $ 109.5  $ 118.3  (7.5) % Adj. fully diluted earnings per share (non-GAAP)  $ 1.53  $ 1.69  (9.5) %

First Quarter 2025

Sales of PYLARIFY were $257.7 million, a decrease of 0.5%. Sales of DEFINITY were $79.2 million, an increase of 3.5%. Operating income decreased 4.3% to $102.1 million. Adjusted operating income (non-GAAP) decreased 7.1% to $144.3 million. Fully diluted earnings per share decreased to $1.02, compared to $1.87 in the prior year period. Adjusted fully diluted earnings per share (non-GAAP) decreased 9.5% to $1.53, compared to $1.69 in the prior year period. Net cash provided by operating activities and free cash flow were $107.6 million and $98.8 million, respectively.

Story Continues

Balance Sheet

At March 31, 2025, the Company's cash and cash equivalents grew to $938.5 million, compared to $912.8 million at December 31, 2024, after prepaying a $50.0 million deposit related to our Evergreen Theragnostics, Inc. (Evergreen) acquisition, which closed early in the second quarter of 2025. The Company currently has access to up to $750.0 million from a revolving line of credit.

Recent Business Highlights

Business Development Updates

In January, the Company announced an agreement to acquire Life Molecular Imaging Ltd. (Life Molecular), which is now expected to close in the second quarter of 2025, subject to customary closing conditions. The acquisition will provide Lantheus with Neuraceq®, a globally approved beta-amyloid targeted radiodiagnostic for Alzheimer’s disease, along with a strong commercial footprint and infrastructure. The deal is complementary to Lantheus’ portfolio of late-stage neurology radiodiagnostics and builds on the acquisition of worldwide rights to LNTH-2401 (68Ga-DOTA-RM2) and LNTH-2402 (177Lu-DOTA-RM2) announced last year. Also in January, the Company announced an agreement to acquire Evergreen, a clinical-stage radiopharmaceutical company based in New Jersey. On April 1, we announced the completion of the acquisition. Through the transaction, Lantheus has acquired OCTEVY™, a registrational-stage PET imaging agent targeting neuroendocrine tumors, which complements Lantheus’ therapeutic candidate PNT2003, as well as acquiring a portfolio of clinical and pre-clinical theranostic pairs. The acquisition also advances Lantheus’ capabilities with the addition of Evergreen’s radioligand therapy manufacturing infrastructure, including a revenue-generating CDMO business. On May 6, 2025, the Company announced the agreement to sell the Company’s SPECT business to Illuminated Holdings, Inc., the parent company of SHINE Technologies, LLC (SHINE). Under the terms of the agreement, SHINE will acquire Lantheus’ SPECT business, including its diagnostic agents (TechneLite, NEUROLITE, Xenon Xe-133 Gas, and Cardiolite), the portion of the North Billerica, MA campus that manufactures Lantheus’ SPECT products and the SPECT-related Canadian operations. The transaction allows Lantheus to focus on growing its commercial portfolio of innovative PET radiodiagnostics and microbubbles, while advancing its pipeline of radiopharmaceuticals. The transaction is expected to close by the end of the year, subject to customary closing conditions.

Radiopharmaceutical Pipeline Updates

Lantheus recently announced that MK-6240, its next-generation tau imaging agent, met its primary endpoints in two pivotal clinical studies assessing the investigational asset’s sensitivity and specificity. The Company plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2025. LNTH-2503, a potentially best- and first-in-class lutetium-177 theranostic pair targeting the cholecystokinin receptor (CCK2R) brought in by the Evergreen acquisition, has been authorized to proceed with a therapeutic Phase 1 study in patients with small cell lung cancer by the European Medicines Agency (EMA). The Company expects to initiate the Phase 1 therapeutic study in the United States later this year and continue its ongoing Phase 2 gallium-68 imaging study. The Phase 3 SPLASH study of PNT2002 recently reached 100% of prespecified overall survival events. The results were comparable to the previously reported 46% and 75% readouts and remain confounded by patient crossover within the study. The Company is working closely with partner, Eli Lilly and Company, to review the full dataset, however the Company does not plan to pursue an NDA or further invest in this asset.

Full Year 2025 Interim Corporate Financial Guidance

Guidance Issued May 7, 2025 Guidance Issued February 26, 2025 FY 2025 Revenue  $1.550 billion - $1.585 billion $1.545 billion - $1.610 billion FY 2025 Adjusted fully diluted EPS  $6.60 - $6.70 $7.00 - $7.20

On a forward-looking basis, the Company does not provide GAAP income per common share guidance or a reconciliation of GAAP income per common share to adjusted fully diluted EPS because the Company is unable to predict with reasonable certainty business development and acquisition related expenses, purchase accounting fair value adjustments, and any one-time, non-recurring charges. These items are uncertain, depend on various factors, and could be material to results computed in accordance with GAAP. As a result, it is the Company’s view that a quantitative reconciliation of adjusted fully diluted EPS on a forward-looking basis is not available without unreasonable effort.

Conference Call and Webcast

As previously announced, the Company will host a conference call and webcast on Wednesday, May 7, 2025, at 8:00 a.m. ET. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events.

A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least 30 days.

The conference call will include a discussion of non-GAAP financial measures. Reference is made to the most directly comparable GAAP financial measures, the reconciliation of the differences between the two financial measures, and the other information included in this press release, our Form 8-K filed with the SEC today, or otherwise available in the Investor Relations section of our website located at www.lantheus.com.

The conference call may include forward-looking statements. See the cautionary information about forward-looking statements in the safe-harbor section of this press release.

About Lantheus Holdings, Inc.

Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for nearly 70 years. For more information, visit www.lantheus.com.

Internet Posting of Information

The Company routinely posts information that may be important to investors in the “Investors” section of its website at www.lantheus.com. The Company encourages investors and potential investors to consult its website regularly for important information about the Company.

Non-GAAP Financial Measures

The Company uses non-GAAP financial measures, such as adjusted net income and its line components; adjusted net income per share - fully diluted; adjusted operating income and its line components, and free cash flow. The Company’s management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company’s operations, period over period. However, these measures may exclude items that may be highly variable, difficult to predict and of a size that could have a substantial impact on the Company’s reported results of operations for a particular period. Management uses these and other non-GAAP measures internally for evaluation of the performance of the business, including the evaluation of results relative to employee performance compensation targets. Investors should consider these non-GAAP measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

Safe Harbor for Forward-Looking and Cautionary Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by their use of terms such as “advance,” “believe,” “continue,” “could,” “driving,” “expect,” “guidance,” “maintain,” “may,” “on track,” “plan,” “potential,” “predict,” “progress,” “should,” “target,” “will,” “would” and other similar terms. Such forward-looking statements include our guidance for the fiscal year 2025 and our plans to expand our portfolio of late-stage assets and high potential early-stage candidates, our acquisition of Evergreen, our potential acquisition of Life Molecular and our plans to divest our SPECT business to SHINE, and are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements include: (i) continued market expansion and penetration for our established commercial products, particularly PYLARIFY and DEFINITY, in a competitive environment and our ability to clinically and commercially differentiate our products; (ii) our ability to have third parties manufacture our products and our ability to manufacture DEFINITY in our in-house manufacturing facility, in amounts and at the times needed; (iii) the availability of raw materials, key components, and equipment, either used in the production of our products and product candidates, or in the use by healthcare professionals of our products and product candidates, including, but not limited to positron emission tomography (“PET”) scanners for PYLARIFY, MK-6240 and NAV-4694; (iv) our ability to satisfy our obligations under our existing clinical development partnerships using MK-6240 or NAV-4694 as a research tool and under the license agreements through which we have rights to MK-6240 and NAV-4694, and to further develop and commercialize MK-6240 and NAV-4694 as approved products, including the timing for any potential regulatory submissions for these investigational assets; (v) our ability to successfully integrate acquisitions, including of Life Molecular, subject to completion of our acquisition thereof, and Evergreen, including the potential for unforeseen expenses related to integration activities, the accuracy of our financial models, the potential for unforeseen liabilities within those businesses, the ability to integrate disparate information technology systems, retain key talent and create a merged corporate culture that successfully realizes the full potential of the combined organization; (vi) our ability to complete the transaction with SHINE on the proposed terms or on the anticipated timeline, or at all, including risks and uncertainties related to securing the necessary regulatory approvals and satisfaction of other closing conditions to consummate the transaction, unforeseen expenses related to the divestiture, and failure to realize the expected benefits of the transaction; (vii) our ability to obtain FDA approval for LNTH-2501, our investigational kit for the preparation of Gallium-68 DOTATOC, which may be used in conjunction with a PET scan to stage and localize gastroenteropancreatic neuroendocrine tumors in adults and children, and approval for PNT2003, and to be successful in the patent litigation associated with PNT2003; (viii) the cost, efforts and timing for clinical development, regulatory approval, adequate coding, coverage and payment and successful commercialization of our product candidates and new clinical applications and territories for our products, in each case, that we or our strategic partners may undertake; (ix) our ability to identify opportunities to collaborate with strategic partners and to acquire or in-license additional diagnostic and therapeutic product opportunities in oncology, neurology and other strategic areas and continue to grow and advance our pipeline of products; and (x) the risk and uncertainties discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q).

- Tables Follow -

Lantheus Holdings, Inc. Consolidated Statements of Operations (in thousands, except per share data – unaudited)  Three Months Ended 
March 31, 2025    2024  Revenues  $ 372,764   $ 369,975  Cost of goods sold   135,064    128,129  Gross profit   237,700    241,846  Operating expenses  Sales and marketing   42,503    45,546  General and administrative   56,816    47,895  Research and development   36,314    48,024  Total operating expenses   135,633    141,465  Gain on sale of assets   —    6,254  Operating income   102,067    106,635  Interest expense   4,804    4,859  Investment in equity securities - unrealized loss (gain)   14,862    (60,704 ) Other income   (14,128 )   (8,788 ) Income before income taxes   96,529    171,268  Income tax expense   23,584    40,202  Net income  $ 72,945   $ 131,066  Net income per common share:  Basic  $ 1.06   $ 1.91  Diluted  $ 1.02   $ 1.87  Weighted-average common shares outstanding:  Basic   68,675    68,757  Diluted   71,461    70,095

Lantheus Holdings, Inc. Consolidated Revenues Analysis (in thousands – unaudited)  Three Months Ended 
March 31, 2025   2024  % Change PYLARIFY  $ 257,654  $ 258,870  (0.5) % Other radiopharmaceutical oncology   —   384  (100.0) % Total radiopharmaceutical oncology   257,654   259,254  (0.6) % DEFINITY   79,211   76,564  3.5 % TechneLite   19,711   21,714  (9.2) % Other precision diagnostics   5,441   5,932  (8.3) % Total precision diagnostics   104,363   104,210  0.1 % Strategic partnerships and other revenue   10,747   6,511  65.1 % Total revenues  $ 372,764  $ 369,975  0.8 %

Lantheus Holdings, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures (in thousands, except per share and percent data – unaudited)  Three Months Ended 
March 31, 2025    2024  Net income  $ 72,945   $ 131,066  Stock and incentive plan compensation   21,198    15,384  Amortization of acquired intangible assets   8,016    9,932  Campus consolidation costs   60    19  Non-recurring fees   2,478    —  Gain on sale of assets   —    (6,254 ) Strategic collaboration and license costs   5,413    28,000  Investment in equity securities - unrealized loss (gain)   14,862    (60,704 ) Acquisition-related costs   4,751    788  Other   (4,452 )   789  Income tax effect of non-GAAP adjustments(a)   (15,796 )   (701 ) Adjusted net income  $ 109,475   $ 118,319  Adjusted net income, as a percentage of revenues   29.4 %   32.0 %

Three Months Ended 
March 31, 2025    2024  Net income per share - diluted  $ 1.02   $ 1.87  Stock and incentive plan compensation   0.30    0.22  Amortization of acquired intangible assets   0.11    0.14  Campus consolidation costs   —    —  Non-recurring fees   0.03    —  Gain on sale of assets   —    (0.09 ) Strategic collaboration and license costs   0.07    0.40  Investment in equity securities - unrealized loss (gain)   0.21    (0.86 ) Acquisition-related costs   0.07    0.01  Other   (0.06 )   0.01  Income tax effect of non-GAAP adjustments(a)   (0.22 )   (0.01 ) Adjusted net income per share - diluted  $ 1.53   $ 1.69  Weighted-average common shares outstanding - diluted   71,461    70,095

(a) The income tax effect of the adjustments between GAAP net income and adjusted net income (non-GAAP) takes into account the tax treatment and related tax rate that apply to each adjustment in the applicable tax jurisdiction.

Lantheus Holdings, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures (Continued) (in thousands, except per share and percent data – unaudited)  Three Months Ended 
March 31, 2025    2024  Operating income  $ 102,067   $ 106,635  Stock and incentive plan compensation   21,198    15,384  Amortization of acquired intangible assets   8,016    9,932  Campus consolidation costs   60    19  Non-recurring fees   2,478    —  Gain on sale of assets   —    (6,254 ) Strategic collaboration and license costs   5,413    28,000  Acquisition-related costs   4,751    788  Other   275    789  Adjusted operating income  $ 144,258   $ 155,293  Adjusted operating income, as a percentage of revenues   38.7 %   42.0 %

Lantheus Holdings, Inc. Reconciliation of Free Cash Flow (in thousands – unaudited)  Three Months Ended 
March 31, 2025    2024  Net cash provided by operating activities $ 107,563   $ 127,238  Capital expenditures  (8,718 )   (8,273 ) Free cash flow $ 98,845   $ 118,965   Net cash used in investing activities $ (63,718 )  $ (106,529 ) Net cash used in financing activities $ (18,219 )  $ (16,845 )

Lantheus Holdings, Inc. Condensed Consolidated Balance Sheets (in thousands – unaudited)  March 31,
2025  December 31,
2024 Assets  Current assets  Cash and cash equivalents $ 938,533   $ 912,814  Accounts receivable, net  348,749    321,258  Inventory  69,126    68,025  Other current assets  67,372    24,536  Total current assets  1,423,780    1,326,633  Investment in equity securities  30,375    39,489  Property, plant and equipment, net  180,783    176,798  Intangibles, net  153,745    161,761  Goodwill  61,189    61,189  Deferred tax assets, net  168,885    170,233  Other long-term assets  36,467    44,237  Total assets $ 2,055,224   $ 1,980,340  Liabilities and stockholders’ equity  Current liabilities  Current portion of long-term debt and other borrowings $ 747   $ 974  Accounts payable  44,874    34,560  Accrued expenses and other liabilities  202,381    204,992  Total current liabilities  248,002    240,526  Asset retirement obligations  18,740    23,344  Long-term debt, net and other borrowings  566,098    565,279  Other long-term liabilities  58,190    63,180  Total liabilities  891,030    892,329  Commitments and contingencies  Stockholders’ equity  Preferred stock ($0.01 par value, 25,000 shares authorized; no shares issued and outstanding)  —    —  Common stock ($0.01 par value, 250,000 shares authorized; 71,607 and 70,905 shares issued as of March 31, 2025 and December 31, 2024, respectively)  716    709  Additional paid-in capital  821,346    817,972  Treasury Stock at cost - 2,455 shares as of March 31, 2025 and December 31, 2024  (175,000 )   (175,000 ) Retained earnings  518,890    445,945  Accumulated other comprehensive loss  (1,758 )   (1,615 ) Total stockholders’ equity  1,164,194    1,088,011  Total liabilities and stockholders’ equity $ 2,055,224   $ 1,980,340

Contacts: 
Mark Kinarney 
Vice President, Investor Relations
978-671-8842
[email protected]

Melissa Downs 
Executive Director, External Communications 
646-975-2533
[email protected]

View Comments